Gardasil HPV Vaccine Hoax Exposed

July 26, 2008 by admin · Leave a Comment 

What if Gardasil has been pushed to make money out of patients? What if Gardasil would be harmful?

Why inject young girls and boys with a dangerous and life threatening vaccine when the herb Pau d’ Arco has been proven to both prevent and cure HPV?

Watch hot news about this Vaccine Hoax !


Genital Warts & Other Effects

July 23, 2008 by admin · Leave a Comment 


HPV Infection

More than 100 types of human papillomavirus (HPV) exist; more than 30 types can infect the genital area. The majority of HPV infections are asymptomatic, unrecognized, or subclinical. Genital HPV infection is common and usually self-limited. Genital HPV infection occurs more frequently than visible Genital Warts among both men and women and cervical cell changes among women.

Genital HPV infection can cause Genital Warts, usually associated with HPV types 6 or 11. Other HPV types that infect the anogenital region (e.g., high-risk HPV types 16, 18, 31, 33, and 35) are strongly associated with cervical neoplasia. Persistent infection with high-risk types of HPV is the most important risk factor for cervical neoplasia.

HPV Tests

A definitive diagnosis of HPV infection is based on detection of viral nucleic acid (i.e., deoxyribonucleic acid [DNA] or ribonucleic acid [RNA]) or capsid protein. Tests that detect several types of HPV DNA in cells scraped from the cervix are available and might be useful in the triage of women with atypical squamous cells of undetermined significance (ASC-US) or in screening women aged >30 years in conjunction with the Papanicolaou (Pap) test (see the NGC summary of the CDC guideline Cervical Cancer Screening for Women Who Attend STD Clinics or Have a History of STDs). Women determined to have HPV infection on such testing should be counseled that HPV infection is common, infection is frequently transmitted between partners, and that infection usually goes away on its own. If any Pap test or biopsy abnormalities have been observed, further evaluation is recommended. Screening women or men with the HPV test, outside of the above recommendations for use of the test with cervical cancer screening, is not recommended.


In the absence of Genital Warts or cervical squamous intraepithelial lesions (SIL), treatment is not recommended for subclinical genital HPV infection, whether it is diagnosed by colposcopy, biopsy, acetic acid application, or through the detection of HPV by laboratory tests. Genital HPV infection frequently goes away on its own, and no therapy has been identified that can eradicate infection. In the presence of coexistent SIL, management should be based on histopathologic findings.

Genital Warts

HPV types 6 or 11 are commonly found before, or at the time of, detection of genital warts; however, the use of HPV testing for genital wart diagnosis is not recommended.

Genital warts are usually flat, papular, or pedunculated growths on the genital mucosa. Diagnosis of genital warts is made by visual inspection and may be confirmed by biopsy, although biopsy is needed only under certain circumstances (e.g., if the diagnosis is uncertain; the lesions do not respond to standard therapy; the disease worsens during therapy; the patient is immunocompromised; or warts are pigmented, indurated, fixed, bleeding, or ulcerated). No data support the use of HPV nucleic acid tests in the routine diagnosis or management of visible genital warts.

The application of 3%-5% acetic acid usually turns HPV-infected genital mucosal tissue to a whitish color. However, acetic acid application is not a specific test for HPV infection, and the specificity and sensitivity of this procedure for screening have not been defined. Therefore, the routine use of this procedure for screening to detect HPV infection is not recommended. However, some clinicians, who are experienced in the management of genital warts, have determined that this test is useful for identifying flat genital warts.

In addition to the external genitalia (i.e., penis, vulva, scrotum, perineum, and perianal skin), genital warts can occur on the uterine cervix and in the vagina, urethra, anus, and mouth. Intra-anal warts are observed predominantly in patients who have had receptive anal intercourse; these warts are distinct from perianal warts, which can occur in men and women who do not have a history of anal sex. In addition to the genital area, HPV types 6 and 11 have been associated with conjunctival, nasal, oral, and laryngeal warts. Genital warts are usually asymptomatic, but depending on the size and anatomic location, genital warts can be painful, friable, or pruritic.

HPV types 16, 18, 31, 33, and 35 are found occasionally in visible genital warts and have been associated with external genital (i.e., vulvar, penile, and anal) squamous intraepithelial neoplasia (i.e., squamous cell carcinoma in situ, bowenoid papulosis, Erythroplasia of Queyrat, or Bowen’s disease of the genitalia). These HPV types also have been associated with vaginal, anal, and CIN and anogenital and some head and neck squamous cell carcinomas. Patients who have visible genital warts are frequently infected simultaneously with multiple HPV types.


The primary goal of treating visible genital warts is the removal of the warts. In the majority of patients, treatment can induce wart-free periods. If left untreated, visible genital warts might resolve on their own, remain unchanged, or increase in size or number. Treatment possibly reduces, but does not eliminate, HPV infection. Existing data indicate that currently available therapies for genital warts might reduce, but probably do not eradicate, HPV infectivity. Whether the reduction in HPV viral DNA, resulting from treatment, impacts future transmission remains unclear. No evidence indicates that the presence of genital warts or their treatment is associated with the development of cervical cancer.


Treatment of genital warts should be guided by the preference of the patient, the available resources, and the experience of the health-care provider. No definitive evidence suggests that any of the available treatments are superior to any other and no single treatment is ideal for all patients or all warts. The use of locally developed and monitored treatment algorithms has been associated with improved clinical outcomes and should be encouraged. Because of uncertainty regarding the effect of treatment on future transmission of HPV and the possibility of spontaneous resolution, an acceptable alternative for some persons is to forego treatment and wait for spontaneous resolution.

The majority of patients have <10 genital warts, with a total wart area of 0.5-1.0 cm2. These warts respond to various treatment modalities. Factors that might influence selection of treatment include wart size, wart number, anatomic site of wart, wart morphology, patient preference, cost of treatment, convenience, adverse effects, and provider experience. Factors that might affect response to therapy include the presence of immunosuppression and compliance with therapy. The majority of patients require a course of therapy rather than a single treatment. In general, warts located on moist surfaces or in intertriginous areas respond better to topical treatment than do warts on drier surfaces.

The treatment modality should be changed if a patient has not improved substantially. The majority of genital warts respond within 3 months of therapy. The response to treatment and its side effects should be evaluated throughout the course of therapy.

Complications occur rarely if treatments for warts are employed properly. Patients should be warned that persistent hypopigmentation or hyperpigmentation occurs commonly with ablative modalities. Depressed or hypertrophic scars are uncommon but can occur, especially if the patient has had insufficient time to heal between treatments. Rarely, treatment can result in disabling chronic pain syndromes (e.g., vulvodynia or analdynia, and hyperesthesia of the treatment site) or, in the case of rectal warts, painful defecation or fistulas. A limited number of case reports of severe systemic effects from podophyllin resin and interferon have been documented.

Treatment regimens are classified into patient-applied and provider-applied modalities. Patient-applied modalities are preferred by some patients because they can be administered in the privacy of the patient’s home. To use patient-applied modalities effectively, compliance with the treatment regimen is important along with the ability to identify and reach all genital warts.

Recommended Regimens for External Genital Warts


  • Podofilox 0.5% solution or gel. Patients should apply podofilox solution with a cotton swab, or podofilox gel with a finger, to visible genital warts twice a day for 3 days, followed by 4 days of no therapy. This cycle may be repeated, as necessary, for up to four cycles. The total wart area treated should not exceed 10 cm2, and the total volume of podofilox should be limited to 0.5 mL per day. If possible, the health-care provider should apply the initial treatment to demonstrate the proper application technique and identify which warts should be treated. The safety of podofilox during pregnancy has not been established.


  • Imiquimod 5% cream Patients should apply imiquimod cream once daily at bedtime, three times a week for up to 16 weeks. The treatment area should be washed with soap and water 6-10 hours after the application. The safety of imiquimod during pregnancy has not been established.


  • Cryotherapy with liquid nitrogen or cryoprobe. Repeat applications every 1-2 weeks.


  • Podophyllin resin 10%-25% in a compound tincture of benzoin. A small amount should be applied to each wart and allowed to air dry. The treatment can be repeated weekly, if necessary. To avoid the possibility of complications associated with systemic absorption and toxicity, two important guidelines should be followed: 1) application should be limited to <0.5 mL of podophyllin or an area of <10 cm2 of warts per session, and 2) no open lesions or wounds should exist in the area to which treatment is administered. Some specialists suggest that the preparation should be thoroughly washed off 1-4 hours after application to reduce local irritation. The safety of podophyllin during pregnancy has not been established.


  • Trichloroacetic acid (TCA) or bichloroacetic acid (BCA) 80%-90%. A small amount should be applied only to the warts and allowed to dry, at which time a white "frosting" develops. If an excess amount of acid is applied, the treated area should be powdered with talc, sodium bicarbonate (i.e., baking soda), or liquid soap preparations to remove unreacted acid. This treatment can be repeated weekly, if necessary.


  • Surgical removal either by tangential scissor excision, tangential shave excision, curettage, or electrosurgery

Alternative Regimens

  • Intralesional interferon


  • Laser surgery

Podofilox 0.5% solution or gel, an antimitotic drug that destroys warts, is relatively inexpensive, easy to use, safe, and self-applied by patients. The majority of patients experience mild-to-moderate pain or local irritation after treatment. Imiquimod is a topically active immune enhancer that stimulates production of interferon and other cytokines. Local inflammatory reactions are common with the use of imiquimod; these reactions include redness and irritation and are usually mild to moderate. Traditionally, follow-up visits are not required for patients using self-administered therapy. However, follow-up might be useful several weeks into therapy to determine the appropriateness of medication use and the response to treatment.

Cryotherapy destroys warts by thermal-induced cytolysis. Health-care providers must be trained on the proper use of this therapy because over- and undertreatment might result in complications or low efficacy. Pain after application of the liquid nitrogen, followed by necrosis and sometimes blistering, is common. Local anesthesia (topical or injected) might facilitate therapy if warts are present in many areas or if the area of warts is large.

Podophyllin resin, which contains several compounds, including antimitotic podophyllin lignans, is another treatment option. The resin is most frequently compounded at 10%-25% in a tincture of benzoin. However, podophyllin resin preparations differ in the concentration of active components and contaminants. The shelf life and stability of podophyllin preparations are unknown. A thin layer of podophyllin resin must be applied to the warts and allowed to air dry before the treated area comes into contact with clothing; overapplication or failure to air dry can result in local irritation caused by spread of the compound to adjacent areas.

Both TCA and BCA are caustic agents that destroy warts by chemical coagulation of proteins. Although these preparations are widely used, they have not been investigated thoroughly. TCA solutions have a low viscosity comparable with that of water and can spread rapidly if applied excessively; therefore, they can damage adjacent tissues. Both TCA and BCA should be applied sparingly and allowed to dry before the patient sits or stands. If pain is intense, the acid can be neutralized with soap or sodium bicarbonate.

Surgical therapy has the advantage of usually eliminating warts at a single visit. However, such therapy requires substantial clinical training, additional equipment, and a longer office visit. After local anesthesia is applied, the visible genital warts can be physically destroyed by electrocautery, in which case no additional hemostasis is required. Care must be taken to control the depth of electrocautery to prevent scarring. Alternatively, the warts can be removed either by tangential excision with a pair of fine scissors or a scalpel or by curettage. Because the majority of warts are exophytic, this procedure can be accomplished with a resulting wound that only extends into the upper dermis. Hemostasis can be achieved with an electrocautery unit or a chemical styptic (e.g., an aluminum chloride solution). Suturing is neither required nor indicated in the majority of cases if surgical removal is performed properly. Surgical therapy is most beneficial for patients who have a large number or area of genital warts. Carbon dioxide laser and surgery might be useful in the management of extensive warts or intraurethral warts, particularly for those patients who have not responded to other treatments.

Interferons, both natural or recombinant, have been used for the treatment of genital warts. They have been administered systemically (i.e., subcutaneously at a distant site or intramuscularly [IM]) and intralesionally (i.e., injected into the warts). Systemic interferon is not effective. The efficacy and recurrence rates of intralesional interferon are comparable to other treatment modalities. Administration of intralesional interferon is associated with stinging, burning, and pain at the injection site. Interferon is probably effective because of its antiviral and/or immunostimulating effects. Interferon therapy is not recommended as a primary modality because of inconvenient routes of administration, frequent office visits, and the association between its use and a high frequency of systemic adverse effects.

Because of the shortcomings associated with all available treatments, some clinics employ combination therapy (i.e., the simultaneous use of two or more modalities on the same wart at the same time). No data support the use of more than one therapy at a time to improve efficacy of treatment, and some specialists believe that combining modalities might increase complications.

Recommended Regimens for Cervical Warts

  • For women who have exophytic cervical warts, high-grade SIL must be excluded before treatment is initiated. Management of exophytic cervical warts should include consultation with a specialist.

Recommended Regimens for Vaginal Warts

  • Cryotherapy with liquid nitrogen. The use of a cryoprobe in the vagina is not recommended because of the risk for vaginal perforation and fistula formation.


  • TCA or BCA 80%-90% applied to warts. A small amount should be applied only to warts and allowed to dry, at which time a white "frosting" develops. If an excess amount of acid is applied, the treated area should be powdered with talc, sodium bicarbonate, or liquid soap preparations to remove unreacted acid. This treatment can be repeated weekly, if necessary.

Recommended Regimens for Urethral Meatus Warts

  • Cryotherapy with liquid nitrogen


  • Podophyllin 10%-25% in compound tincture of benzoin. The treatment area must be dry before contact with normal mucosa. This treatment can be repeated weekly, if necessary. The safety of podophyllin during pregnancy has not been established.

Although data evaluating the use of podofilox and imiquimod for the treatment of distal meatal warts are limited, some specialists recommend their use in some patients.

Recommended Regimens for Anal Warts

  • Cryotherapy with liquid nitrogen


  • TCA or BCA 80%-90% applied to warts. A small amount should be applied only to warts and allowed to dry, at which time a white "frosting" develops. If an excess amount of acid is applied, the treated area should be powdered with talc, sodium bicarbonate, or liquid soap preparations to remove unreacted acid. This treatment can be repeated weekly, if necessary.


  • Surgical removal

Warts on the rectal mucosa should be managed in consultation with a specialist. Many persons with warts on the anal mucosa also have warts on the rectal mucosa, so persons with anal warts can benefit from an inspection of the rectal mucosa by digital examination or anoscopy.


Genital HPV Infection

Education and counseling are vital aspects of managing patients with genital warts. Patients can be educated through patient education materials, including pamphlets, hotlines, and websites (> or

Attempts should be made to convey the following key messages:

  • Genital HPV infection is common among sexually active adults. The majority of sexually active adults will have it at some point in their lives, although the majority of them will never know because the infection usually has no symptoms and clears on its own.
  • Genital HPV infection is usually sexually transmitted. The incubation period (i.e., the interval between initial exposure and established infection or disease) is variable, and determining the timing and source of infection is frequently difficult. Within ongoing sexual relationships, sex partners usually are infected by the time of the patient’s diagnosis, although they might have no symptoms or signs of infection.
  • No recommended uses of the HPV test to diagnose HPV infection in sex partners have been established. HPV infection is commonly transmitted to partners but usually goes away on its own.

Genital Warts

  • Genital warts are caused by specific types of HPV infection. The types that cause genital warts are different from the types that cause cervical and other anogenital cancers.
  • Persons can possibly have infection with the types of HPV that cause genital warts but never develop symptoms. Why some persons with genital HPV infection develop warts and others do not is unclear. Immunity probably plays a key role.
  • The natural history of genital warts is usually benign, but recurrence of genital warts within the first several months after treatment is common. Treatment for genital warts can reduce HPV infection, but whether the treatment results in a reduction in risk for transmission of HPV to sex partners is unclear. The duration of infectivity after wart treatment is unknown.
  • Condoms might reduce the risk for HPV-associated diseases (e.g., genital warts and cervical cancer). Consistent condom use also may reduce the risk for genital HPV. HPV infection can occur in areas that are not covered or protected by a condom (e.g., scrotum, vulva, or perianus).
  • The presence of genital warts is not an indication for HPV testing, a change in the frequency of Pap tests, or cervical colposcopy.
  • HPV testing is not indicated for partners of persons with genital warts.


After visible genital warts have cleared, a follow-up evaluation might be helpful. Patients should be cautioned to watch for recurrences, which occur most frequently during the first 3 months. External genital warts can be difficult to identify, so it might be useful for patients to have a follow-up evaluation 3 months after treatment. Earlier follow-up visits also might be useful for some patients to document the absence of warts, to monitor for or treat complications of therapy, and to provide an additional opportunity for patient education and counseling. Women should be counseled to undergo regular Pap screening as recommended for women without genital warts.

Management of Sex Partners

Examination of sex partners is not necessary for the management of genital warts because no data indicate that reinfection plays a role in recurrences. In addition, providing treatment for genital warts solely for the purpose of preventing future transmission cannot be recommended because the value of treatment in reducing infectivity is unknown. However, sex partners of patients who have genital warts might benefit from counseling and examination to assess the presence of genital warts and other STDs. The counseling of sex partners provides an opportunity for these partners to 1) learn that HPV infection is common and probably shared between partners and 2) receive STD evaluation and screening and Pap screening if they are female. Female sex partners of patients who have genital warts should be reminded that cytologic screening for cervical cancer is recommended for all sexually active women.

Special Considerations


Imiquimod, podophyllin, and podofilox should not be used during pregnancy. However, because genital warts can proliferate and become friable during pregnancy, many specialists advocate their removal during pregnancy. HPV types 6 and 11 can cause respiratory papillomatosis in infants and children. The route of transmission (i.e., transplacental, perinatal, or postnatal) is not completely understood. Whether cesarean section prevents respiratory papillomatosis in infants and children is unclear; therefore, cesarean delivery should not be performed solely to prevent transmission of HPV infection to the newborn. Cesarean delivery might be indicated for women with genital warts if the pelvic outlet is obstructed or if vaginal delivery would result in excessive bleeding. Pregnant women with genital warts should be counseled concerning the low risk for warts on the larynx (recurrent respiratory papillomatosis) in their infants or children. No controlled studies have suggested that cesarean section prevents this condition.

HIV Infection

No data suggest that treatment modalities for external genital warts should be different in the setting of HIV-infection. However, persons who are immunosuppressed because of HIV or other reasons might have larger or more numerous warts, might not respond as well as immunocompetent persons to therapy for genital warts, and might have more frequent recurrences after treatment. Squamous cell carcinomas arising in or resembling genital warts might occur more frequently among immunosuppressed persons, therefore, requiring biopsy for confirmation of diagnosis. Because of the increased incidence of anal cancer in HIV-infected homosexual men, screening for anal SIL by cytology in this population is recommended by some specialists. However, evidence is limited concerning the natural history of anal intraepithelial neoplasias, the reliability of screening methods, the safety and response to treatments, and the programmatic considerations that would support this screening approach. Until additional data are generated on screening for anal SIL, this screening approach cannot be recommended.

Squamous Cell Carcinoma in Situ

Patients in whom squamous cell carcinoma in situ of the genitalia is diagnosed should be referred to a specialist for treatment. Ablative modalities usually are effective, but careful follow-up is essential. The risk for these lesions leading to invasive squamous cell carcinoma of the external genitalia in immunocompetent patients is unknown but is probably low. Female partners of male patients who have squamous cell carcinoma in situ are at high risk for cervical abnormalities.







Genital Warts

July 22, 2008 by admin · Leave a Comment 

Genital Warts (or condyloma) is a Sexually Transmitted Disease (STD) caused by the human papilloma virus (HPV). The virus may cause wart-like bumps to form on the penis, in and around the vagina, on the cervix (opening to the womb), around the anus (butt), and rarely on the mouth. The virus is passed between people during anal, vaginal, and sometimes oral sex. These are NOT the same warts commonly found on hands and feet.

How are Genital Warts spread?

Many people carry the wart virus on their penis, in and around the vagina, or in and around the anus/rectum. Only a small number of these people develop warts that can be seen. It is passed with skin to skin contact during anal or vaginal sex. The wart virus is very common in adults who are sexually active.
How do I know if I have warts?

Not everyone with the genital wart virus will have signs of disease. You may have painless wart-like growths on or in your sex organs or around your anus (butt). The warts may vary in size and be bumpy or flat. Sometimes special tests are needed to detect the wart virus.

Are Genital Warts serious?

They can be. For most people warts are only a bother, and are treated if you wish. If a woman has warts on the cervix (opening to the womb), they can be a problem. It is rare, but sometimes having warts can cause a woman to have a pap smear that is not normal, (including changes that may lead to cancer). For this reason, women with warts on the cervix should have a pap smear test (part of a pelvic exam) every six months to one year. Men and women who have warts on or inside the anus should have an exam every year.
What can I do if I have genital warts?

Be sure you see a clinician (licensed medical provider).
Keep all your return treatment appointments.
Your sex partner(s) should also be seen and treated.
If you may be pregnant, tell your clinician.
If you have sex, it is always a good idea to use a condom to avoid getting STDs.
However, condom use is not a 100% protection from the wart virus.
How are genital warts treated?

A clinician puts a cold liquid chemical on the warts to remove them.
You may need to come back more than once to finish the wart treatment.
You may need longer treatment if you have HIV. The warts may increase in size and number more quickly. Tell your clinician if you are HIV positive.
Will the warts come back?

Warts may return, even after treatment, this is because the virus stays in your skin once you are infected. You can pass the virus to your sex partners during vaginal or anal sex, even when you don’t have warts you can see.
How can I avoid getting genital warts?

Check yourself often for signs of actual warts; these can be treated. But remember: we treat the wart, not the virus, which stays in the skin.
Use condoms (rubbers) every time you have sex. Condoms reduce your risk for getting warts, but they won’t guarantee protection. Condoms also help to prevent other STDS.

Risk Factors for Cervical Cancer

Early onset of sexual intercourse (< 18 years of age)
Multiple sex partners (3+ lifetime)
Male partners with multiple partners
Sexual partners of men whose previous sex partners developed cervical cancer
Cigarette smoking
History of HPV infection (subtypes 16, 18 – not external)
Protective Factors

Life-long mutual monogamy
Use of condoms and spermicides


July 21, 2008 by admin · Leave a Comment 

What is herpes?

Herpes is one of the most common viral infections in the United States. One of every four Americans over 18 has been exposed to genital herpes. Most people don’t know they’re infected.

What causes herpes?

Herpes is a viral infection of the skin caused by the herpes simplex virus (HSV). There are two types of herpes: HSV-1 and HSV-2.

HSV-1 usually causes infections of the mouth such as "cold sores" or "fever blisters" on the lips. Most of the time HSV-2 causes genital herpes. But, either type of herpes can cause an infection of the mouth or genitals.

Herpes is spread by direct skin-to-skin contact with someone who is infected. You can get herpes from someone who has sores on his or her lips, skin or genitals. But, most of the time, herpes is spread when someone does not have any signs or symptoms. The herpes virus can still rub off a person’s skin even when he or she has no sores that you can see.

Remember: you can get herpes from someone who has no sores or symptoms and if you have herpes you can spread it even if you have no sores or symptoms.

What are the signs and symptoms?

Only about half the people who get herpes have symptoms. Those who do have symptoms usually have an outbreak two to 10 days, or within three weeks, after they get the virus. The first symptoms are usually the worst. They are called primary herpes.

Signs and symptoms may include:

  • A fever, headache, and muscle aches. Three days later, painful blisters and skin ulcers appear where you were infected. This may be your mouth, genital area, anus and/or rectum.
  • Sores usually appear on both sides of the genitals during the first outbreak.
  • Blisters may be "hidden" in your vagina.
  • About a week after the skin rash, tender and swollen glands, or lymph nodes, may develop in your groin.

If you do not get treatment, your rash and pain will usually go away within three to four weeks.

Your sores will heal, but the virus will never go away. It will always stay in your body in a latent form. This means it will be quiet, hidden, and you will not have symptoms. But, herpes can become active again and cause new sores. This is called "recurrent" herpes.

  • The second time you have symptoms, they will usually hurt less and not be as bad as the first time. Recurrent herpes often starts with a burning or itchy feeling one to two days before a skin rash begins.
  • The sores of recurrent herpes usually appear on only one side of your genitals.

Can herpes cause any more problems?

The most severe problem (complication) happens when a woman passes the virus to her baby during delivery. If the infant is infected, it is very serious. This infection often causes the baby to die or suffer mental retardation and blindness. This problem is rare and usually happens when a woman gets herpes for the first time near delivery. If a woman has a Genital Herpes outbreak when she goes into labor, she may need a C-section (Cesarean delivery).

Urinating may be very painful if you have sores on your vulva (the external parts of the female genitals). You may be more comfortable if you sit in a tub of warm water and urinate into the bath water.

It is rare, but the first time you have herpes, it can cause the nerves to your bladder to become inflamed. If this happens, you will not be able to urinate. This is a temporary problem. You should see a health care provider for treatment.

How will I know if I have herpes?

If you have any sores, blisters, or red areas on your genitals your health care provider should examine you. He or she will swab the area to test for the virus. If you don’t have any sores, a blood test can be done to see if you have ever been exposed to herpes.

Is there a cure?

No. Herpes is a chronic, lifelong infection. It will never go away. Even though there is no cure, antiviral medicines can help to:

  • Treat the symptoms,
  • Lower your chances of having an outbreak,
  • Lower the number of times you shed the virus without knowing it, and
  • Prevent you from having the symptoms again.

Medicines include:

These work best if you take them at the first sign of burning or itching, before the sores appear. Another way to take them is to take a small amount each day. Acyclovir is given to newborns who are infected during birth.

What about my partner(s)?

Because herpes is a sexually transmitted disease (STD), your sex partners should be checked for symptoms. Many partners do not have symptoms that can be seen or felt. But, your partners still need to be checked for infection and other STDs.

Since herpes is a lifelong infection, it is important to talk openly and honestly with your partners. If you’d like advice about how to talk to your partners, call one of the numbers at the end of this fact sheet.

When can I have sex again?

You should not have oral, vaginal or anal sex when you have sores. Also do not have any kind of sex if you think you might be getting an outbreak. Remember: you can pass the virus to your partners even when you do not have symptoms.

You should tell your current and future partners that you have herpes.

How can I prevent herpes?

Not having sex (abstinence) is the only sure way to avoid infection.

To lower your chances of giving or getting herpes, use latex or polyurethane condoms every time you have oral, vaginal or anal sex. Using these condoms the right way each time you have sex can reduce your risk of genital herpes. Using condoms will not totally stop the risk of giving or getting herpes because this disease is spread through skin-to-skin contact from sores/ ulcers OR infected skin that may look normal. Condoms also help prevent the spread of other STDs including HIV, the virus that causes AIDS.

If you are sexually active, you and your partners should get a full physical checkup. This includes a complete sexual history and testing for common STDs. You should be checked for gonorrhea, chlamydia, syphilis, herpes, Genital Warts, trichomoniasis, and HIV.

Will anyone know the results of the exams?

Your test results and any treatment will be kept absolutely confidential. No one can find out your results, except you. If you are under 18 you can be checked and treated for STDs without getting permission from your parents.

To learn more:

If you have more questions about herpes, or you want to know how to find a clinic near you, call your local health department. You may also call the Herpes Hotline at: 1-919-361-8488. You can reach them from 9:00 a.m. to 7:00 p.m. Monday to Friday. Your local Planned Parenthood office also has information about local herpes support groups.

You may also call the National STD Hotline at 1-800-CDC-INFO 1-800-232-4636.

Genital Herpes

July 21, 2008 by admin · Leave a Comment 


What is genital herpes?

Genital herpes is a sexually transmitted disease (STD) caused by the herpes simplex viruses type 1 (HSV-1) or type 2 (HSV-2). Most Genital Herpes is caused by HSV-2. Most individuals have no or only minimal signs or symptoms from HSV-1 or HSV-2 infection. When signs do occur, they typically appear as one or more blisters on or around the genitals or rectum. The blisters break, leaving tender ulcers (sores) that may take two to four weeks to heal the first time they occur. Typically, another outbreak can appear weeks or months after the first, but it almost always is less severe and shorter than the first outbreak.  Although the infection can stay in the body indefinitely, the number of outbreaks tends to decrease over a period of years.

How common is genital herpes?

Results of a nationally representative study show that Genital Herpes infection is common in the United States. Nationwide, at least 45 million people ages 12 and older, or one out of five adolescents and adults, have had genital HSV infection. Over the past decade, the percent of Americans with Genital Herpes infection in the U.S. has decreased.

Genital HSV-2 infection is more common in women (approximately one out of four women) than in men (almost one out of eight). This may be due to male-to-female transmission being more likely than female-to-male transmission.

How do people get genital herpes?

HSV-1 and HSV-2 can be found in and released from the sores that the viruses cause, but they also are released between outbreaks from skin that does not appear to have a sore. Generally, a person can only get HSV-2 infection during sexual contact with someone who has a genital HSV-2 infection. Transmission can occur from an infected partner who does not have a visible sore and may not know that he or she is infected.

HSV-1 can cause genital herpes, but it more commonly causes infections of the mouth and lips, so-called “fever blisters.” HSV-1 infection of the genitals can be caused by oral-genital or genital-genital contact with a person who has HSV-1 infection. Genital HSV-1 outbreaks recur less regularly than genital HSV-2 outbreaks.

What are the signs and symptoms of genital herpes?

Most people infected with HSV-2 are not aware of their infection. However, if signs and symptoms occur during the first outbreak, they can be quite pronounced. The first outbreak usually occurs within two weeks after the virus is transmitted, and the sores typically heal within two to four weeks. Other signs and symptoms during the primary episode may include a second crop of sores, and flu-like symptoms, including fever and swollen glands. However, most individuals with HSV-2 infection  never have sores, or they have very mild signs that they do not even notice or that they mistake for insect bites or another skin condition.

People diagnosed with a first episode of Genital Herpes can expect to have several (typically four or five) outbreaks (symptomatic recurrences) within a year. Over time these recurrences usually decrease in frequency.  It is possible that a person becomes aware of the “first episode” years after the infection is acquired.

What are the complications of genital herpes?

Genital herpes can cause recurrent painful genital sores in many adults, and herpes infection can be severe in people with suppressed immune systems. Regardless of severity of symptoms, genital herpes frequently causes psychological distress in people who know they are infected. To soothe those symptoms Herpeset has been very helpful

In addition, genital HSV can lead to potentially fatal infections in babies. It is important that women avoid contracting herpes during pregnancy because a newly acquired infection during late pregnancy poses a greater risk of transmission to the baby. If a woman has active genital herpes at delivery, a cesarean delivery is usually performed. Fortunately, infection of a baby from a woman with herpes infection is rare.

Herpes may play a role in the spread of HIV, the virus that causes AIDS. Herpes can make people more susceptible to HIV infection, and it can make HIV-infected individuals more infectious.

How is genital herpes diagnosed?

The signs and symptoms associated with HSV-2 can vary greatly. Health care providers can diagnose genital herpes by visual inspection if the outbreak is typical, and by taking a sample from the sore(s) and testing it in a laboratory. HSV infections can be diagnosed between outbreaks by the use of a blood test. Blood tests, which detect  antibodies to HSV-1 or HSV-2 infection, can be helpful, although the results are not always clear-cut.

Is there a treatment for herpes?

There is no treatment that can cure herpes, but antiviral medications can shorten and prevent outbreaks during the period of time the person takes the medication.  In addition, daily suppressive therapy for symptomatic herpes can reduce transmission to partners.

How can herpes be prevented?

The surest way to avoid transmission of sexually transmitted diseases, including genital herpes, is to abstain from sexual contact, or to be in a long-term mutually monogamous relationship with a partner who has been tested and is known to be uninfected.

Genital ulcer diseases can occur in both male and female genital areas that are covered or protected by a latex condom, as well as in areas that are not covered. Correct and consistent use of latex condoms can reduce the risk of genital herpes.

Persons with herpes should abstain from sexual activity with uninfected partners when lesions or other symptoms of herpes are present. It is important to know that even if a person does not have any symptoms he or she can still infect sex partners. Sex partners of infected persons should be advised that they may become infected and they should use condoms to reduce the risk. Sex partners can seek testing to determine if they are infected with HSV. A positive HSV-2 blood test most likely indicates a genital herpes infection.


« Previous PageNext Page »